HC Wainwright & Co. Reiterates Buy on Avadel Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27. Analyst Oren Livnat continues to support the stock, indicating confidence in its potential growth.
August 28, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27. Analyst Oren Livnat continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and maintenance of a $27 price target by a reputable analyst suggests positive sentiment and potential upside for Avadel Pharmaceuticals. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100